NO20003414D0 - Anvendelse av PPAR-<ypsilon> aktivatorer i dermatologi - Google Patents

Anvendelse av PPAR-<ypsilon> aktivatorer i dermatologi

Info

Publication number
NO20003414D0
NO20003414D0 NO20003414A NO20003414A NO20003414D0 NO 20003414 D0 NO20003414 D0 NO 20003414D0 NO 20003414 A NO20003414 A NO 20003414A NO 20003414 A NO20003414 A NO 20003414A NO 20003414 D0 NO20003414 D0 NO 20003414D0
Authority
NO
Norway
Prior art keywords
ppar
ypsilon
dermatology
activators
anomaly
Prior art date
Application number
NO20003414A
Other languages
English (en)
Other versions
NO20003414L (no
NO325171B1 (no
Inventor
Michel Rivier
Irina Safonova
Serge Michel
Original Assignee
Galderma Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Res & Dev filed Critical Galderma Res & Dev
Publication of NO20003414D0 publication Critical patent/NO20003414D0/no
Publication of NO20003414L publication Critical patent/NO20003414L/no
Publication of NO325171B1 publication Critical patent/NO325171B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20003414A 1997-12-31 2000-06-29 Anvendelse av minst en aktivator av reseptorer av PPAR-gamma type for fremstilling av et farmasoytisk, mer spesielt dermatologisk, preparat. NO325171B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9716808A FR2773075B1 (fr) 1997-12-31 1997-12-31 Utilisation d'activateurs de ppar-gamma en dermatologie
PCT/FR1998/002894 WO1999034783A1 (fr) 1997-12-31 1998-12-28 UTILISATION D'ACTIVATEURS DE PPAR-η EN DERMATOLOGIE

Publications (3)

Publication Number Publication Date
NO20003414D0 true NO20003414D0 (no) 2000-06-29
NO20003414L NO20003414L (no) 2000-08-31
NO325171B1 NO325171B1 (no) 2008-02-11

Family

ID=9515385

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20003414A NO325171B1 (no) 1997-12-31 2000-06-29 Anvendelse av minst en aktivator av reseptorer av PPAR-gamma type for fremstilling av et farmasoytisk, mer spesielt dermatologisk, preparat.

Country Status (13)

Country Link
US (1) US6403656B1 (no)
EP (1) EP1041977B1 (no)
JP (1) JP3773790B2 (no)
AT (1) ATE402698T1 (no)
AU (1) AU745187B2 (no)
BR (1) BR9815340A (no)
CA (1) CA2314607C (no)
DE (1) DE69839815D1 (no)
ES (1) ES2310019T3 (no)
FR (1) FR2773075B1 (no)
NO (1) NO325171B1 (no)
NZ (1) NZ505089A (no)
WO (1) WO1999034783A1 (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9908647D0 (en) * 1999-04-15 1999-06-09 Smithkline Beecham Plc Novel compounds
US20040034067A1 (en) * 1999-04-15 2004-02-19 Macphee Colin Houston Novel method of treatment
US20030148924A1 (en) * 2002-07-09 2003-08-07 Tamar Tennenbaum Methods and pharmaceutical compositions of healing wounds
CA2416788A1 (en) * 2000-07-31 2002-02-07 Tamar Tennenbaum Methods and pharmaceutical compositions comprising protein kinase c isoforms for healing wounds
US20100129332A1 (en) * 2000-07-31 2010-05-27 Tamar Tennenbaum Methods and pharmaceutical compositions for healing wounds
US20040037828A1 (en) * 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
EP1331934B1 (de) * 2000-11-09 2006-03-29 Phenion GmbH &amp; Co KG Ppar-alpha,beta-aktivatoren zur behandlung von alopecia areata und vitiligo
EP1385516A1 (en) * 2001-04-30 2004-02-04 Arachnova Therapeutics Ltd. The treatment of scarring and related conditions using ppar-gamma activators
DE10204398A1 (de) * 2002-02-04 2003-08-14 Univ Goettingen Georg August Neue Verwendung von Liganden der 'Peroxisome Proliferator-Activated receptors'(PPAR)
US20040115637A1 (en) * 2002-12-11 2004-06-17 Isis Pharmaceuticals Inc. Modulation of PPAR-alpha expression
GB0303600D0 (en) * 2003-02-17 2003-03-19 Glaxo Group Ltd Novel therapeutic method and compositions
EP1651161B1 (en) 2003-08-07 2011-10-19 HealOr Ltd. Pharmaceutical compositions and methods for accelerating wound healing
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
US20070086967A1 (en) * 2003-12-03 2007-04-19 Brian Macdonald Treatment of psoriasis with rosiglitazone
JP4556511B2 (ja) * 2004-06-25 2010-10-06 ソニー株式会社 １５ｄ−ＰＧＪ２、及び、１５ｄ−ＰＧＪ２を用いた方法
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ZA200802546B (en) * 2005-08-29 2009-10-28 Healor Ltd Methods and compositions for prvention and treatment of diabetic and aged skin
KR100702415B1 (ko) * 2006-03-03 2007-04-09 안웅식 올리고 핵산 탐침 비드 어레이를 이용한 인유두종바이러스검출 키트 및 방법
CN102755649A (zh) * 2007-07-30 2012-10-31 希尔洛有限公司 药物组合物及相关方法
US20090291986A1 (en) * 2008-05-22 2009-11-26 Apostolos Pappas Composition and method of treating facial skin defect
US20090291066A1 (en) * 2008-05-22 2009-11-26 Apostolos Pappas composition and method of treating facial skin defect
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
HUE032999T2 (hu) 2009-02-16 2017-11-28 Nogra Pharma Ltd Alkilamido vegyületek és azok alkalmazása
ES2601827T3 (es) * 2009-02-24 2017-02-16 Arava Bio-Tech Ltd. Agentes antagonistas de visfatina para el tratamiento del acné y de otras afecciones
AR073505A1 (es) * 2009-09-10 2010-11-10 Monte Verde S A Composiciones y metodos para el tratamiento de enfermedades proliferativas
EP2523677A2 (en) 2010-01-11 2012-11-21 Healor Ltd. Method for treatment of inflammatory disease and disorder
US20110274775A1 (en) * 2010-05-07 2011-11-10 Michael Anthonavage Extracts of southernwood and topical uses thereof
US20110274776A1 (en) * 2010-05-07 2011-11-10 Michael Anthonavage Compositions comprising extracts of southernwood and an amine compound
ES2397889B1 (es) 2011-03-25 2014-02-07 Lipotec, S.A. PÉPTIDOS MODULADORES DE PGC-1Alfa.
MX364220B (es) 2012-02-09 2019-04-16 Nogra Pharma Ltd Metodos de tratamientos de fibrosis.
EP2844242A1 (en) 2012-04-18 2015-03-11 Nogra Pharma Limited Methods of treating lactose intolerance
FR3049864A1 (fr) 2016-04-06 2017-10-13 Naturex Extrait vegetal issu d'une plante du genre aerva, composition le contenant et utilisation dudit extrait vegetal
KR20210125047A (ko) 2019-02-08 2021-10-15 노그라 파마 리미티드 3-(4'-아미노페닐)-2-메톡시프로피온산, 및 그의 유사체 및 중간체의 제조 방법
IT202000027489A1 (it) * 2020-11-17 2022-05-17 Mauro Michele Maria Picardo Attivatori selettivi dei recettori attivati da proliferatori peroxisomiali (PPARs) per il trattamento della vitiligine
CN116548385B (zh) * 2023-04-20 2023-10-27 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 自发型系统性红斑狼疮动物模型的构建方法及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04507397A (ja) * 1988-01-14 1992-12-24 フリッツ，アンデルス 湿疹治療用薬剤製造における必須脂肪酸の使用法
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
US5443844A (en) * 1992-12-03 1995-08-22 Mcdaniel; William R. Linoleic acid preparations for topical treatment of acne vulgaris
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
SE9403158D0 (sv) * 1994-09-21 1994-09-21 Pharmacia Ab New use of prostaglandins
US6022897A (en) * 1995-04-25 2000-02-08 The Salk Institute For Biological Studies Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
WO1998008089A1 (en) * 1996-08-23 1998-02-26 Arch Development Corporation Identification of activators and inhibitors of sebum formation
DE69739828D1 (de) * 1996-12-11 2010-05-12 Dana Farber Cancer Inst Inc Methoden und pharmazeutische Zusammensetzungen zur Inhibition des Tumorwachstums
PL334840A1 (en) * 1997-01-24 2000-03-27 Univ California Application of fxr, pparalpha and lxralpha activators in order to restore the barrier function, to stimulate epithelium differentation and to inhibit proliferation
US6060515A (en) * 1997-01-24 2000-05-09 The Regents Of The University Of California Treatment of skin conditions by use of PPARα activators
US5925657A (en) * 1997-06-18 1999-07-20 The General Hospital Corporation Use of PPARγ agonists for inhibition of inflammatory cytokine production

Also Published As

Publication number Publication date
NO20003414L (no) 2000-08-31
NZ505089A (en) 2002-12-20
JP2002500179A (ja) 2002-01-08
FR2773075A1 (fr) 1999-07-02
EP1041977A1 (fr) 2000-10-11
NO325171B1 (no) 2008-02-11
WO1999034783A1 (fr) 1999-07-15
BR9815340A (pt) 2000-10-31
CA2314607C (fr) 2009-02-03
CA2314607A1 (fr) 1999-07-15
DE69839815D1 (de) 2008-09-11
ATE402698T1 (de) 2008-08-15
ES2310019T3 (es) 2008-12-16
AU745187B2 (en) 2002-03-14
US6403656B1 (en) 2002-06-11
EP1041977B1 (fr) 2008-07-30
AU2057599A (en) 1999-07-26
FR2773075B1 (fr) 2000-05-05
JP3773790B2 (ja) 2006-05-10

Similar Documents

Publication Publication Date Title
NO20003414L (no) Anvendelse av PPAR-&lt;ypsilon&gt; aktivatorer i dermatologi
AR010062A1 (es) Nuevos benzamidaldehidos y su utilizacion
EA200100058A1 (ru) 4-бензилпиперидиналкилсульфоксидные гетероциклические соединения и их применение в качестве подтип-избирательных антагонистов nmda-рецепторов
ATE134368T1 (de) Substituierte imidazole und ihre verwendung als hemmmstoff fur angiotensin ii
SE9504661D0 (sv) New compounds
TR200102800T2 (tr) Yeni bileşikler.
DK0833839T3 (da) Heterocykliske peptidylforbindelser, der er nyttige til behandling af thrombinrelaterede sygdomme
ATE402170T1 (de) N,n-disubstituierte amide welche die bindung von integrinen an ihre rezeptoren hemmen
TR199901172T2 (xx) Yeni ikame edilmi� pirazol t�revleri.
ES2191208T3 (es) Oxiimino-pregnano-carbolactonas.
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
PT772603E (pt) Compostos substituidos de pirimidina e sua utilizacao
ATE284853T1 (de) Ureido-thiobuttersäurederivate als ppar-agonisten
UA42795C2 (uk) Протизапальний засіб для зовнішнього застосування, що містить німесулід, і спосіб його одержання
DE69530933D1 (de) Verwendung von 5-(tetradecyloxy)-2-furan carbonsäure für die behandlung von alzheimer krankheit oder psychosis
DE60045508D1 (de) Dalda-analoge und ihre verwendung
TR200100426T2 (tr) Nematisit pirazoller
NO971341D0 (no) Promoter for reseptor tyrosinkinase TIE
DE69523155T2 (de) Benzimidazolonderivate mit zentraler dopaminerger aktivität
TR200200263T2 (tr) Yeni seçiçi retinoid agonistleri
MX9704050A (es) P-amidinobencilamidas de dipeptido novedosas con radicales sulfonilo o aminosulfonilo en terminal n.
ES2156642T3 (es) Composicion que comprende un derivado de acido cinamico y un polimero poliaminado.
ATE272436T1 (de) Mikrofiltration unter verwendung von aktivkohle
ATE253930T1 (de) Behandlung von follikulären lymphomen unter verwendung von inhibitoren des lymphotoxin (lt)- aktivierungsweges
DE69803383T2 (de) Selektive inhibitoren des faktors x, eine azepinonstruktur enthaltend

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees